Clinical trial · Interventional
Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer
A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer
NCT01667211CI-TRIAL-00007869CSAPPPCCunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Using albumin-bound paclitaxel and nedaplatin in the advanced or recurrent metastasis cervical cancer, to evaluate the efficacy and toxic reaction.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| albumin-bound paclitaxel plus nedaplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- albumin-bound paclitaxel plus nedaplatin
- description
- albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
- interventionNames
- Drug: albumin-bound paclitaxel plus nedaplatin
Primary outcomes (1)
- measure
- response rate
- timeFrame
- one year
- description
- Percentage of patients who achieve partial response (PR)/ complete response (CR) based on RECIST
Secondary outcomes (4)
- measure
- Time to progression (TTP)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Cervical cancer, advanced or recurrent metastasis * Measurable and assessible tumor lesions * Used ordinary paclitaxel or platinum drugs, more than 28 days * Aged 18-70 * KPS score\> 60 points, expected to survive more than 3 months * Normal bone marrow function * The function of liver and kidney had no obvious damage * Normal function of vital organs * No brain metastases * Patients or their agents to sign informed consent * Compliance, and can be followed up regularly Exclusion Criteria: * Brain metastases * Serious complications * Acute inflammatory response * Combined with other tumor * Pregnancy or breast-feeding women * Vertebral metastasis with nerve compression symptoms * Large volume of pleural effusion, pericardial effusion * Other malignancy within five years * Drug allergy * Other chemotherapy contraindications * The possibility of pregnancy, and not willing to contraception * No measurement of lesion * Mental illness which is difficult to control
References
Publications (0)
Data not yet available
No reference posted for this study.